Colorectal cancer models for novel drug discovery

Expert Opinion on Drug Discovery

Volumn 10, Issue 11, 2015, Pages 1217-1229

  Golovko, Daniel ^a   Kedrin, Dmitriy ^b,c   Yilmaz, Ömer H ^b,c   Roper, Jatin ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

colorectal cancer mouse models; intestinal organoid; patient derived xenograft; transgenic colorectal cancer mouse model

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOGEN; CRE RECOMBINASE; SHORT HAIRPIN RNA;

CANCER CELL CULTURE; CANCER CELL LINE; CANCER MODEL; CANCER THERAPY; CANCER TISSUE; CANCER TRANSPLANTATION; CHEMICAL CARCINOGENESIS; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CRISPR CAS SYSTEM; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; FAMILIAL COLON POLYPOSIS; GASTROINTESTINAL POLYPOSIS; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC MANIPULATION; GENETICALLY ENGINEERED MOUSE STRAIN; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CRYPT; LIVER METASTASIS; METASTASIS; MISMATCH REPAIR; MOUSE MODEL; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ANIMAL; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG DEVELOPMENT; DRUG SCREENING; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE; TRANSLATIONAL RESEARCH;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; TRANSLATIONAL MEDICAL RESEARCH; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946493726     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1079618     Document Type: Review

References (101)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87-108
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-15
3. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6(10):813-23
4. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366(10):883-92
5. MacLeod RA, Dirks WG, Matsuo Y, et al. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 1999;83(4):555-63
6. Chen TR, Drabkowski D, Hay RJ, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet Cytogenet 1987;27(1):125-34
7. Corbett TH, Griswold DP Jr, Roberts BJ, et al. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975;35(9):2434-9
8. Brattain MG, Strobel-Stevens J, Fine D, et al. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 1980;40(7):2142-6
9. Martin ES, Belmont PJ, Sinnamon MJ, et al. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin Cancer Res 2013;19(11):2929-40
10. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009;459(7244):262-5
11. Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011;141(5):1762-72
12. Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 2013;340(6137):1190-4
13. Ootani A, Li X, Sangiorgi E, et al. Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat Med 2009;15(6):701-6
14. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457(7229):608-11
15. Onuma K, Ochiai M, Orihashi K, et al. Genetic reconstitution of tumorigenesis in primary intestinal cells. Proc Natl Acad Sci USA 2013;110(27):11127-32
16. Schwank G, Koo BK, Sasselli V, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 2013;13(6):653-8
17. Li X, Nadauld L, Ootani A, et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med 2014;20(7):769-77
18. Jung P, Sato T, Merlos-Suarez A, et al. Isolation and in vitro expansion of human colonic stem cells. Nat Med 2011;17(10):1225-7
19. Miyoshi H, Stappenbeck TS. In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture. Nat Protoc 2013;8(12):2471-82
20. Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med 2015;21(3):256-62
21. Drost J, van Jaarsveld RH, Ponsioen B, et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 2015;521(7550):43-7
22. van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015;161(4):933-45
23. Croy BA, Linder KE, Yager JA. Primer for non-immunologists on immune-deficient mice and their applications in research. Comp Med 2001;51(4):300-13
24. Blunt T, Gell D, Fox M, et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci U S A 1996;93(19):10285-90
25. Talmadge JE, Singh RK, Fidler IJ, et al. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007;170(3):793-804
26. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9(11):4227-39
27. Rosfjord E, Lucas J, Li G, et al. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol 2014;91(2):135-43
28. Tignanelli CJ, Herrera Loeza SG, Yeh JJ. KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages. Am Surg 2014;80(9):873-7
29. Burgenske DM, Monsma DJ, Dylewski D, et al. Establishment of genetically diverse patient-derived xenografts of colorectal cancer. Am J Cancer Res 2014;4(6):824-37
30. Julien S, Merino-Trigo A, Lacroix L, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012;18(19):5314-28
31. Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 2013;73(17):5315-19
32. Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011;10(8):1311-16
33. Morelli MP, Calvo E, Ordonez E, et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol 2012;30(4):e45-8
34. Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer 2015;15(5):311-16
35. Cespedes MV, Espina C, Garcia-Cabezas MA, et al. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 2007;170(3):1077-85
36. Zigmond E, Halpern Z, Elinav E, et al. Utilization of murine colonoscopy for orthotopic implantation of colorectal cancer. PLoS One 2011;6(12):e28858
37. Yui S, Nakamura T, Sato T, et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5(+) stem cell. Nat Med 2012;18(4):618-23
38. Reddy BS, Weisburger JH, Narisawa T, et al. Colon carcinogenesis in germ-free rats with 1,2-dimethylhydrazine and N-methyl-n′-nitro-N-nitrosoguanidine. Cancer Res 1974;34(9):2368-72
39. Kobaek-Larsen M, Thorup I, Diederichsen A, et al. Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans. Comp Med 2000;50(1):16-26
40. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2007;2(8):1998-2004
41. Clapper ML, Cooper HS, Chang WC. Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol Sin 2007;28(9):1450-9
42. De Robertis M, Massi E, Poeta ML, et al. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog 2011;10:9
43. Nishikawa A, Imazawa T, Kuroiwa Y, et al. Induction of colon tumors in C57BL/6J mice fed MeIQx, IQ, or PhIP followed by dextran sulfate sodium treatment. Toxicol Sci 2005;84(2):243-8
44. Clapper ML, Gary MA, Coudry RA, et al. 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 2008;14(10):1341-7
45. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124(2):361-7
46. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247(4940):322-4
47. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256(5057):668-70
48. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66(3):589-600
49. Sansom OJ, Meniel VS, Muncan V, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007;446(7136):676-9
50. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275(5307):1787-90
51. Swamy MV, Patlolla JM, Steele VE, et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006;66(14):7370-7
52. Boivin GP, Washington K, Yang K, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003;124(3):762-77
53. Cheung AF, Carter AM, Kostova KK, et al. Complete deletion of Apc results in severe polyposis in mice. Oncogene 2010;29(12):1857-64
54. Colnot S, Niwa-Kawakita M, Hamard G, et al. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab Invest 2004;84(12):1619-30
55. Fodde R, Edelmann W, Yang K, et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 1994;91(19):8969-73
56. Kuraguchi M, Wang XP, Bronson RT, et al. Adenomatous polyposis coli (APC) is required for normal development of skin and thymus. PLoS Genet 2006;2(9):e146
57. Oshima M, Oshima H, Kitagawa K, et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA 1995;92(10):4482-6
58. Quesada CF, Kimata H, Mori M, et al. Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice. Jpn J Cancer Res 1998;89(4):392-6
59. Robanus-Maandag EC, Koelink PJ, Breukel C, et al. A new conditional Apc-mutant mouse model for colorectal cancer. Carcinogenesis 2010;31(5):946-52
60. Smits R, Kartheuser A, Jagmohan-Changur S, et al. Loss of Apc and the entire chromosome 18 but absence of mutations at the Ras and Tp53 genes in intestinal tumors from Apc1638N, a mouse model for Apc-driven carcinogenesis. Carcinogenesis 1997;18(2):321-7
61. Roper J, Martin ES, Hung KE. Overview of genetically engineered mouse models of colorectal carcinoma to enable translational biology and drug development. Curr Protoc Pharmacol 2014;65:14-29
62. Roper J, Hung KE. Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. Trends Pharmacol Sci 2012;33(8):449-55
63. Edelmann W, Umar A, Yang K, et al. The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res 2000;60(4):803-7
64. Edelmann W, Yang K, Kuraguchi M, et al. Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Res 1999;59(6):1301-7
65. Edelmann W, Yang K, Umar A, et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997;91(4):467-77
66. Reitmair AH, Redston M, Cai JC, et al. Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice. Cancer Res 1996;56(16):3842-9
67. Washington MK, Powell AE, Sullivan R, et al. Pathology of rodent models of intestinal cancer: progress report and recommendations. Gastroenterology 2013;144(4):705-17
68. Kuraguchi M, Yang K, Wong E, et al. The distinct spectra of tumor-associated Apc mutations in mismatch repair-deficient Apc1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis. Cancer Res 2001;61(21):7934-42
69. Shoemaker AR, Haigis KM, Baker SM, et al. Mlh1 deficiency enhances several phenotypes of Apc(Min)/+ mice. Oncogene 2000;19(23):2774-9
70. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 2003;306(4):799-804
71. Takaku K, Oshima M, Miyoshi H, et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998;92(5):645-56
72. Engle SJ, Hoying JB, Boivin GP, et al. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999;59(14):3379-86
73. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359(6397):693-9
74. Zhu Y, Richardson JA, Parada LF, et al. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998;94(6):703-14
75. el Marjou F, Janssen KP, Chang BH, et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 2004;39(3):186-93
76. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449(7165):1003-7
77. Powell AE, Wang Y, Li Y, et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 2012;149(1):146-58
78. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004;18(12):1385-90
79. Hinoi T, Akyol A, Theisen BK, et al. Mouse model of colonic adenomacarcinoma progression based on somatic Apc inactivation. Cancer Res 2007;67(20):9721-30
80. Xue Y, Johnson R, Desmet M, et al. Generation of a transgenic mouse for colorectal cancer research with intestinal cre expression limited to the large intestine. Mol Cancer Res 2010;8(8):1095-104
81. Byun AJ, Hung KE, Fleet JC, et al. Colon-specific tumorigenesis in mice driven by Cre-mediated inactivation of Apc and activation of mutant Kras. Cancer Lett 2014;347(2):191-5
82. Shibata H, Toyama K, Shioya H, et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 1997;278(5335):120-3
83. Hung KE, Maricevich MA, Richard LG, et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A 2010;107(4):1565-70
84. Coffee EM, Faber AC, Roper J, et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 2013;19(10):2688-98
85. Roper J, Sinnamon MJ, Coffee EM, et al. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Lett 2014;347(2):204-11
86. Belmont PJ, Budinska E, Jiang P, et al. Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease. Dis Model Mech 2014;7(6):613-23
87. Dow LE, Nasr Z, Saborowski M, et al. Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice. PLoS One 2014;9(4):e95236
88. Dow LE, Fisher J, O'Rourke KP, et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol 2015;33(4):390-4
89. Dow LE, O'Rourke KP, Simon J, et al. Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer. Cell 2015;161(7):1539-52
90. Trobridge P, Knoblaugh S, Washington MK, et al. TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology 2009;136(5):1680-8e7
91. Chen HJ, Yang BL, Chen YG, et al. A GFP-labeled human colon cancer metastasis model featuring surgical orthotopic implantation. Asian Pac J Cancer Prev 2012;13(9):4263-6
92. Kuo TH, Kubota T, Watanabe M, et al. Liver colonization competence governs colon cancer metastasis. Proc Natl Acad Sci USA 1995;92(26):12085-9
93. Morimoto-Tomita M, Ohashi Y, Matsubara A, et al. Mouse colon carcinoma cells established for high incidence of experimental hepatic metastasis exhibit accelerated and anchorage-independent growth. Clin Exp Metastasis 2005;22(6):513-21
94. Bouvet M, Tsuji K, Yang M, et al. In vivo color-coded imaging of the interaction of colon cancer cells and splenocytes in the formation of liver metastases. Cancer Res 2006;66(23):11293-7
95. Alamo P, Gallardo A, Pavon MA, et al. Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models. Dis Model Mech 2014;7(3):387-96
96. Alamo P, Gallardo A, Di Nicolantonio F, et al. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB J 2015;29(2):464-76
97. Donigan M, Loh BD, Norcross LS, et al. A metastatic colon cancer model using nonoperative transanal rectal injection. Surg Endosc 2010;24(3):642-7
98. de Jong GM, Aarts F, Hendriks T, et al. Animal models for liver metastases of colorectal cancer: research review of preclinical studies in rodents. J Surg Res 2009;154(1):167-76
99. Chen HJ, Sun J, Huang Z, et al. Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting. Nat Biotechnol 2015;33(6):656-60
100. Williams SA, Anderson WC, Santaguida MT, et al. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Invest 2013;93(9):970-82
101. Uronis JM, Osada T, McCall S, et al. Histological and molecular evaluation of patient-derived colorectal cancer explants. PLoS One 2012;7(6):e38422